New AI-enabled, integrated workflow provides pharma and
biotech companies with comprehensive R&D insights to help
minimize late-stage failures during clinical trials
LONDON, Dec. 5, 2023 /PRNewswire/
-- Clarivate Plc (NYSE:CLVT), a global leader in
connecting people and organizations to intelligence they can trust
to transform their world, today announced the launch of VeriSIM
Life Translational Index™ on Cortellis Drug Discovery Intelligence
by Clarivate. The integrated workflow provides customers with a
diverse array of predictive compound safety and efficacy insights,
including bioavailability, hepatic and renal clearance, clinical
toxicity, first-in-human dose and more.
The new solution serves as the next phase of an expanding
partnership between Clarivate and VeriSIM Life, the leading
artificial intelligence (AI)-enabled, R&D decisions de-risker
for breakthrough drug development, announced earlier this year.
Robert Poolman, Senior Vice
President Life Sciences & Healthcare Products, Clarivate,
said: "As emerging technology continues to evolve to address
the growing needs of biotechs, pharmas and patients alike, drug
developers can leverage AI to reduce research and development time
and increase clinically active compound candidates, all while
meeting government regulations and standards. In partnership with
VeriSIM Life, the Translational Index for Clarivate leverages AI to
address these unmet needs, improving pre-clinical success rates and
ultimately equipping our customers with the insight and foresight
needed to create innovative treatments, deliver them to patients
faster and create a healthier tomorrow."
Jo Varshney, CEO &
Founder, VeriSIM Life, commented: "The science of translating
medicinal candidates to safe and effective therapies is extremely
complex. We recognize that researchers need solutions which
complement their workflows and scientific methods while improving
the probability of clinical success. The expansion of our
integration with Clarivate is natural evolution for scientific
discovery within research organizations advancing the next
generation of life saving medicines. It also allows drug program
owners to manage the risk of asset development much more
effectively."
The FDA deems the cost and time associated with translating drug
candidates to successful clinical trial outcomes to be
"unsustainable" for the pharmaceutical
industry.1 Accurate objective data and
predictive analytics are needed to enable informed decision-making
and pharma and biopharma organizations must optimize their tools to
efficiently translate data into insights that can accelerate drug
development.
This solution seamlessly integrates VeriSIM Life Translational
Index™, an innovative approach to helping researchers make early
and accurate predictions about compound safety and efficacy, with
Cortellis Drug Discovery Intelligence by Clarivate, a leading
source of pharma and drug research and development intelligence.
Customers can access enhanced R&D insights to help better
evaluate the therapeutic potential of key compounds. These insights
serve as a material aid to fuel informed experimentation and
decision-making, guiding critical aspects of drug development,
including the route of administration, dosing, toxicity, human
variability, and other key requirements in the drug development
cycle.
Through the integration of the VeriSIM Life Translational Index
and Cortellis Drug Discovery Intelligence, researchers can now
access more comprehensive insights to help accelerate the
preclinical translation phase of drug development by augmenting
Cortellis Drug Discovery Intelligence and OFF-X data with
comprehensive, AI-enabled insights on toxicology, species-specific
drug exposure, and clinical translatability, even in the absence of
published data, empowering them to make informed decisions with
statistical power.
As a provider of best-in-class data integration/deidentified
patient solutions and a premier end-to-end research intelligence
solution, Clarivate is committed to comprehensively supporting
customers across the entire drug, device or diagnostic product
lifecycle to help them advance human health. Clarivate will
continue to invest in artificial intelligence (AI) and machine
learning (ML) that supports the industry's ever-growing need to
engage patients, physicians and payers in new ways, navigate
barriers to access and adherence, and address patient unmet
needs.
To learn more about VeriSIM Life Translational Index™ and
Cortellis Drug Discovery Intelligence, visit here.
About VeriSIM Life
VeriSIM Life has developed a sophisticated computational
platform that leverages advanced AI and ML techniques to improve
drug discovery and development by significantly reducing the time
and money it takes to bring a drug to market. BIOiSIM® is a
first-in-class 'virtual drug development engine' that offers
unprecedented value for the drug development industry by narrowing
down the number of drug compounds that offer anticipated value for
the treatment or cure of specific illnesses or diseases. The
platform predicts the likelihood of a candidate's success in
clinical trials early in the preclinical stage, while reducing
unnecessary experimentation and better informing key program
decisions. For more information,
visit www.verisimlife.com.
About Clarivate
Clarivate™ is a leading global information services provider. We
connect people and organizations to intelligence they can trust to
transform their perspective, their work and our world. Our
subscription and technology-based solutions are coupled with deep
domain expertise and cover the areas of Academia & Government,
Life Sciences & Healthcare and Intellectual Property. For more
information, please visit www.clarivate.com.
1 US Food and Drug Administration. Speech to the
Regulatory Affairs Professionals Society (RAPS) 2017 Regulatory
Conference. September
2017. https://www.fda.gov/news-events/speeches-fda-officials/speech-regulatory-affairs-professionals-society-raps-2017-regulatory-conference-09112017
Media Contact:
Luna Ivkovic
External Communications, Life Sciences & Healthcare
newsroom@clarivate.com
Logo -
https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/clarivate-expands-partnership-with-verisim-life-to-accelerate-and-de-risk-research-and-drug-development-302004721.html